Navigation Links
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
Date:6/14/2013

://www.simcere.com/">http://www.simcere.com.

Bristol-Myers Squibb Forward Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that Orencia SC will become a commercially successful product in China. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Simcere Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. These forward looking statements are based upon management
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
2. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
3. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
4. Life Technologies to Partner with Bristol-Myers Squibb for Companion Diagnostics Development
5. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
6. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
11. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... VANCOUVER, British Columbia , May 30, 2015 /PRNewswire/ ... today that results from a retrospective analysis of the ... therapy in men with metastatic castrate-resistant prostate cancer (CRPC) ... effect of clusterin inhibition in men at risk for ... in the trial had at least two of five ...
(Date:5/30/2015)... CAMBRIDGE, Massachusetts y SPARTANBURG ... 30, 2015 - Nueva ... clínico terapéutico para pacientes con cáncer en los ... Research Network y Molecular Health proporcionarán a los ...   La Guardian Research Network y ...
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
Breaking Medicine Technology:OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 2Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 3Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6
... 2011 ConvaTec Healthcare, a world-leading developer, manufacturer and ... care, today announced that, following a review of current ... refinancing of its senior secured term loans originally entered ... ConvaTecConvaTec is a leading developer and marketer of innovative ...
... March 17, 2011 Giant Eagle®, the region,s leading ... Association,s (ADA) prestigious Chairman,s Citation Award. Giant ... which recognizes the outstanding accomplishments of individuals, corporations, institutions ... and have had a positive impact in advancing the ...
Cached Medicine Technology:ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 2ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 3Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 2Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 3
(Date:5/30/2015)... York, New York (PRWEB) May 30, 2015 ... to pay $100 million in punitive and compensatory ... ) plaintiff who suffered serious complications following implantation ... According to a verdict rendered on May 28th ... $25 million in compensatory damages after the jury ...
(Date:5/30/2015)... Belton, Texas (PRWEB) May 30, 2015 ... Client Services Web Portal that gives hospices the ability ... the industry. Because of this business model, EHO has ... offer better pricing to its clients and survive among ... interface with hospice management systems three years ago, it ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Nicole ... the Disability Income Associate (DIA) designation to further ... DIA designation is designed for insurance advisors, health ... further their knowledge and expertise associated with the ... the DIA designation is only the latest accomplishment ...
(Date:5/30/2015)... 30, 2015 The Brain Fitness Education ... with ONEgeneration Senior Enrichment Center, headed by 1Heart Client ... Guzman and Brain Fitness Program Director Tee Barr. , ... learned that there are many ways to enrich and ... the residents the different ways to overcome dementia and ...
(Date:5/30/2015)... Wixom, Michigan: Proof. Pest Control, a family-owned company ... new twist to its robust line of services-a 100% ... for general pest management. , “We like killing ... Branch Manager. “The average person cringes when they see a ... problems that most people don’t even want to think about. ...
Breaking Medicine News(10 mins):Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:Proof. Pest Control-Now Offering 100% Organic Pest Control in Southeast Michigan 2
... Dr. Khanna has found PRELEX is better than Lasik for individuals over ... longer lasting, prevents the development of cataracts, and does not induce dry ... ... Dr. Khanna has found PRELEX is better than Lasik for individuals ...
... The Generic Pharmaceutical Association (GPhA) released the following statement ... the nomination of Dr. Margaret Hamburg as Commissioner and ... Food and Drug Administration (FDA)."GPhA stands ready to work ... the Agency as it carries out its mission to ...
... reduce itching, improve quality of life, study finds , , ... Chinese medicine, including tea and acupuncture, may safely and ... finds. , Use of Erka Shizheng Herbal ... months greatly reduced the severity of the itchy, red ...
... with Updated Interoperability Requirements , ... ... -- The Certification Commission for Healthcare Information Technology (CCHIT®) ... 4.0.1 is a CCHIT Certified® 08 Ambulatory EHR meets ...
... Kurzweil , described by Forbes magazine as "the ultimate ... (D-IA), health and wellness expert Dr. Deepak Chopra , ... and Chief Scientific Officer Dr. Mehmood Khan and three ... Race and Reconciliation in America: Health and Wellness for ...
... As a result of the FDA expanding the Peanut Corporation of ... lla related recall to include all peanut ingredient ... Weaver Popcorn Company, Inc. has issued a precautionary voluntary recall for ... , s End (R) Chocolatey Peanut ...
Cached Medicine News:Health News:PRELEX is the Answer for Baby Boomers Vision Needs 2Health News:GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA 2Health News:Advanced Data System's MedicsDocAssistant™ EHR Receives 08 CCHIT Certification 2Health News:Advanced Data System's MedicsDocAssistant™ EHR Receives 08 CCHIT Certification 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 2Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 4Health News:Weaver Popcorn Company Issues a Nationwide Precautionary Voluntary Recall of 12 oz. (340g) Trail's End(R) Chocolatey Peanut Clusters 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: